glp-1/gip/glucagon triple agonist retatrutide glp-1 gip glucagon phase 3 2025 Dual and Triple Gut Peptide Agonists Why target one pathway when

Description

Diabetes: from research to clinical practice: Volume 4 [Internet]

Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia

Patients were not randomly assigned to one of the two dose groups

Also Phase three studies are underway for MASLD with these drugs

10 In particular, semaglutide was most successful at reducing alanine transaminase (mean difference, 14.70 U/L), aspartate transaminase (mean difference, 9.32 U/L), g-glutamyl transferase (mean difference, 16.56 U/L), and liver stif fness measurement (mean difference, 3.08 kPa) compared with the other medications studied, whereas liraglutide demonstrated efficacy in reducing subcutaneous adipose tissue (mean difference, 30.27 cm 2 ) and liver fat fraction (mean difference, 5.16%)